CLINICAL GUIDELINES FOR DIAGNOSTICS AND EARLY INTERVENTION IN PRIMARY ALDOSTERONISM
RESEARCHER PROFILE
Associate Professor Jun Yang (Filmed May 2024)
Head of Endocrine Hypertension Group, Hudson Institute of Medical Research
Consultant Endocrinologist at Monash Health &
Senior Researcher in Department of Medicine at Monash University, Victoria, Australia
Associate Professor Jun Yang is the Head of the Endocrine Hypertension Group at Hudson Institute of Medical Research, Consultant Endocrinologist at Monash Health and Senior Researcher in the Department of Medicine at Monash University, Victoria, Australia.
Yang graduated from Monash University with a MBBS (Hon) in 2001, obtained the FRACP in 2010 and completed her PhD on tissue-selective coregulators of the mineralocorticoid receptor (MR) in 2013.
She has continued basic and clinical research in the field of MR-driven cardiovascular disease, in particular, primary aldosteronism. Primary Aldosteronism (PA), or Conn Syndrome, is the most commonly under-diagnosed cause of high blood pressure affecting millions of people. Jun’s goal is to facilitate the diagnosis of every case of PA and make treatment widely available to all communities including the disadvantaged.
She established the Endocrine Hypertension Service in 2016 and co-leads the NHMRC Centre of Research Excellence in Primary Aldosteronism.
“My main interest lies in the translation of primary aldosteronism research into revised clinical guidelines, improved diagnostic tools and transformed practice to help patients. In addition, I am identifying the earliest point of disease occurrence with the aim of enabling earlier intervention and return to health”, says Associate Professor Yang.
Together with national and international collaborators, her research program seeks to improve the detection and understanding of primary aldosteronism to achieve improved patient outcomes.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Next generation nanomedicine and radiopharmaceuticals to treat cancer
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
-
Behavioural science in cancer screening, control and communication
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
